Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 5Ovarian Neoplasms 3Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Healthy Participants 2Endometrial Neoplasms 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumour 1Neoplasm Metastasis 1Moderate Hepatic Impairment 1Melanoma 1Hereditary Sensory and Autonomic Neuropathies 1Hematologic Neoplasms 1Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer) 1Fallopian Tube Neoplasms 1Chondrosarcoma 1Advanced Solid Tumours 1Advanced Solid Malignancy, 1Advanced Solid Malignancy 1Advanced Cancer 1

Interventions

capivasertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Moderate Hepatic Impairment × capivasertib × Clear all
NCT07343960 2026-05-20

A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment

AstraZeneca

Phase 1 Recruiting
20 enrolled

Moderate Hepatic Impairment

Data powered by HemOnc (CC BY 4.0) Colophon âš¡